Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04256941
Title	Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	M.D. Anderson Cancer Center
Indications	estrogen-receptor positive breast cancer progesterone-receptor positive breast cancer
Therapies	Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole
Age Groups:	adult \| senior
Covered Countries	USA